Intraperitoneal (IP) Cisplatin Given With Paclitaxel to Treat Epithelial Ovarian Cancer

NCT00889733 | Terminated Phase 1 DMC

• 1 other identifier: OVHM-01
• Study Type: interventional
• Target: 9
• Locations: 1 country
• Sites: 1

Brief Summary

The purpose of this study is to determine whether intraperitoneal (IP) Cisplatin combined with intravenous (IV) Paclitaxel is well tolerated in women with epithelial ovarian cancer who have had neoadjuvant chemotherapy followed by initial debulking surgery.

Conditions

Epithelial Ovarian Cancer

Outcome Measures

Primary Outcomes (1)

• Safety and Dose Tolerance

  Day 1 of each cycle and assessed every 3 months in follow-up (if applicable)

Secondary Outcomes (1)

• Time to progression

  Day 1 of cycle 1 & 2 and every 3 months in follow-up until progression noted

Study Arms (1)

IP Cisplatin

EXPERIMENTAL

Patients with epithelial ovarian cancer who have undergone optimal debulking surgery receive IP Cisplatin with IV Paclitaxel.

Drug: Intraperitoneal (IP) Cisplatin

Interventions

Intraperitoneal (IP) Cisplatin DRUG

For patients who have had neoadjuvant chemotherapy followed by optimal debulking surgery they go on to receive combined IP Cisplatin and IV Paclitaxel.

IP Cisplatin

Eligibility Criteria

• Age: 18 Years - 75 Years
• Sex: female
• Healthy Volunteers: No
• Age Groups: Adult (18-64), Older Adult (65+)

You may qualify if:

• Histologically proven epithelial ovarian cancer
• Previously received no more than 4 cycles of neoadjuvant platinum based chemotherapy, followed by debulking surgery
• ECOG PFS \<\_ 2
• Adequate haematological (absolute neutrophil count \>\_ 1,500/mm3; platelets \>\_ 100,000/mm3; hemoglobin \>\_ 100g/L); renal (\<\_ upper limit of normal) and hepatic function
• Age \>\_ 18 years
• Written informed consent and the ability of the patient to co-operate with treatment and follow up

You may not qualify if:

• Contraindication to platinum/Paclitaxel chemotherapy: prior anaphylaxis to Carboplatin/Paclitaxel, unresolved or excessive toxicity from neoadjuvant chemotherapy. Patients must not have suffered significant bone marrow suppression during prior treatment. The significance of previous treatment delay and/or dose modification is to be determined by the Principle Investigator on a patient-by-patient basis.
• Serious concomitant medical condition, which in the investigators opinion would not make the patient a good candidate for the clinical trial.
• Patients with a past or concomitant malignancy other than skin cancer (excluding melanoma)
• Patients known to be serologically positive for Hepatitis B, C or HIV
• History of congestive heart failure or unstable angina or those who had a myocardial infarction within the past 6 months. Patients who were not expected to tolerate the hemodynamic effects of the fluid administered as part of the IP protocol.
• Patients who have not received chemotherapy prior to surgery
• Greater than 6 weeks from time of surgery to commencement of IP chemotherapy
• Residual disease greater than 1 cm at time of surgery. Patients whom in the surgeon's opinion are candidates for such surgery may be consented preoperatively to allow intraoperative IP catheter insertion. If however the surgeon is not able to reduce the bulk of disease to less than or equal to 1 cm, patients will be removed from the study and an IP catheter SHOULD NOT be placed.

Sponsors & Collaborators

• University Health Network, Toronto: lead
• Princess Margaret Hospital, Canada: collaborator

Study Sites (1)

University Health Network - Princess Margaret Hospital

Toronto, Ontario, M5G 2M9, Canada

Location

MeSH Terms

Conditions

Carcinoma, Ovarian Epithelial

Interventions

Infusions, Parenteral; Cisplatin

Condition Hierarchy (Ancestors)

Carcinoma; Neoplasms, Glandular and Epithelial; Neoplasms by Histologic Type; Neoplasms; Ovarian Neoplasms; Endocrine Gland Neoplasms; Neoplasms by Site; Ovarian Diseases; Adnexal Diseases; Genital Diseases, Female; Female Urogenital Diseases; Female Urogenital Diseases and Pregnancy Complications; Urogenital Diseases; Genital Neoplasms, Female; Urogenital Neoplasms; Genital Diseases; Endocrine System Diseases; Gonadal Disorders

Intervention Hierarchy (Ancestors)

Drug Administration Routes; Drug Therapy; Therapeutics; Chlorine Compounds; Inorganic Chemicals; Nitrogen Compounds; Platinum Compounds

Study Officials

• Helen MacKay, MD

  UHN - Princess Margaret Cancer Centre

  PRINCIPAL INVESTIGATOR

Study Design

• Study Type: interventional
• Phase: phase 1
• Allocation: NA
• Masking: NONE
• Purpose: TREATMENT
• Intervention Model: SINGLE GROUP
• Sponsor Type: OTHER
• Responsible Party: SPONSOR

Study Record Dates

• First Submitted: April 27, 2009
• First Posted: April 29, 2009
• Study Start: February 1, 2007
• Primary Completion: July 1, 2009
• Study Completion: December 1, 2009
• Last Updated: March 26, 2024

Record last verified: 2024-03

Locations

CA (1)